Resumen
Objective: To compare the outcomes of the COVID-19 patients who used the COVID Kit in their treatment with those who did not. Methods: This was a single-center, analytical, cross-sectional, and observational study. Results: The study included 49 COVID-19-positive patients; from those, 65.4% were over 50 years old, 50.0% were male, 36.5% were brown, 44.2% obese, and 73.1% had morbidity. Patients who used the COVID Kit had a higher prevalence of altered platelets, creatine phosphokinase, liver function, and cardiac arrhythmias, with significant changes in intestinal function and potassium level. However, mortality proportions were equal between groups. Conclusion: Patients who used the COVID Kit had a higher prevalence of adverse effects, including changes in clinical and laboratory tests. In addition, the COVID-19 Kit did not decrease mortality in these patients.
Citas
Ciotti M, Ciccozzi M, Terrinoni A, Jiang WC, Wang CB, Bernardini S. The COVID-19 pandemic. Crit Rev Clin Lab Sci. 2020;57(6):365-88. https://doi.org/10.1080/10408363.2020.1783198
Duarte DB, Coelho LJ, Nascimento GNL. Atualidades da farmacoterapia da covid-19. Desafios. Revista Interdisciplinar da Universidade Federal do Tocantins. 2020;7(Especial-3):81-9. https://doi.org/10.20873/uftsuple2020-8983
Silva JNB, Brito MES, Souza Júnior DA, Silva AS. A ivermectina possui ação terapêutica na covid-19? In: Mendes AA, editors. Proceedings of the 1st Congresso Online de Geriatria e Gerontologia do UNIFACIG; 2020 Jul 27-31; [place unknown]. Anais do Congresso de Geriatria e Gerontologia do UNIFACIG [Internet]. 2020 [cited 2021 Nov 29];1(1). Available from: https://pensaracademico.unifacig.edu.br/index.php/congressogeriatria/article/view/2317/1556
Mallhi TH, Ahmad A, Butt MH, Misbah S, Khan YH, Alotaibi NH. Chloroquine and hydroxychloroquine in COVID-19: practice implications for a healthcare professionals. J Coll Physicians Surg Pak [Internet]. 2020 [cited 2022 Jan 15];30(JCPSPCR):CR124-CR128. Available from: https://jcpsp.pk/article-detail/chloroquine-and-hydroxychloroquine-in-covid19-practice-implications-for-healthcare-professionals
Imperador CHL, Espreafico Junior CRE, Antonio MVN, Chin CM, Bosquesi PL. Cloroquina e hidroxicloroquina associado ao zinco e/ou azitromicina na COVID-19. ULAKES Journal of Medicine [Internet]. 2020 [cited 2021 Nov 28];1(EE):67-73. Available from: https://revistas.unilago.edu.br/index.php/ulakes/article/view/258
Moura JM, Silva LM, Souza RF, Ramos DVB. Indicação e uso de azitromicina no tratamento do COVID-19: revisão da literatura. Braz J Dev. 2021;7(6):56547-56. https://doi.org/10.34117/bjdv7n6-185
Menezes CR, Sanches C, Chequer FMD. Efetividade e toxicidade da cloroquina e da hidroxicloroquina associada (ou não) à azitromicina para tratamento da COVID-19. O que sabemos até o momento?. Journal of Health and Biological Sciences. 2020;8(1):1-9. https://doi.org/10.12662/2317-3076jhbs.v8i1.3206.p1-9.2020
Souza JB, Medeiros SMFRS, Cavalcanti IDL, Coriolano DL, Soares JCS, Oliveira FHPC. Hidroxicloroquina como alternativa para o tratamento da infecção causada pelo SARS-CoV-2: O que se sabe até agora? Brazilian Journal of Health Review. 2020;3(3):4255-73. https://doi.org/10.34119/bjhrv3n3-029
Wu TC, Sacilotto L, Darrieux FCC, Pisani CF, Melo SL, Hachul DT, et al. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19. Arq Bras Cardiol. 2020;114(6):1061-6. https://doi.org/10.36660/abc.20200389
Viqueira EB, Pulido JC, Bulpe MJI. Torsade de pointes. Revista Clínica de Medicina de Familia [Internet]. 2016 [cited 2021 Oct 18];9(1):63-7. Available from: https://scielo.isciii.es/pdf/albacete/v9n1/paciente6.pdf
Malta M, Cardoso LO, Bastos FI, Magnanini MMF, Silva CMFP. STROBE initiative: guidelines on reporting observational studies. Rev Saude Publica. 2010;44(3):559-65. https://doi.org/10.1590/S0034-89102010000300021
Cespedes MS, Souza JCRP. Coronavirus: a clinical update of Covid-19. Rev Assoc Med Bras. 2020;66(2):116-23. https://doi.org/10.1590/1806-9282.66.2.116
Mattos AF. Cloroquina e Hidroxicloroquina: Seus Efeitos no Tratamento da COVID-19. Ensaios e Ciência. Ciências Biológicas, Agrárias e da Saúde. 2021;25(4):468-72. https://doi.org/10.17921/1415-6938.2021v25n4p468-472
The RECOVERY Collaborative Group. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383(21):2030-40. https://doi.org/10.1056/NEJMoa2022926
Caramelli B, Mello C, Pinto FS, Jacintho JD, Abboud MHM. Conselho federal de medicina, prescrição off label e tratamento precoce para a COVID-19. RDM [Internet]. 2021 [cited 2022 Feb 7];9(3):1-33. Available from: https://www.ceciliamelloadvogados.com.br/wp-content/uploads/2021/08/RTDoc-31-08-2021-Revista-de-Direito-e-Medicina.pdf
Soares FR, Dadalto L. Responsabilidade médica e prescrição off-label de medicamentos no tratamento da COVID-19. Revista IBERC [Internet]. 2020 [cited 2022 Feb 7];3(2):1-22. https://doi.org/10.37963/iberc.v3i2.112
Ministério Público Federal (BR), Procuradoria da República no Estado de São Paulo. Parecer de 08 de fevereiro de 2022. Discute a suspensão do parecer 4/2020 do CFM e que o Conselho oriente ostensivamente a comunidade médica e a população em geral sobre a ineficácia de cloroquina e hidroxicloroquina no tratamento da COVID-19 [Internet]. São Paulo: Procuradoria da República no Estado de São Paulo; 2022 [cited 2022 Feb 14]. Available from: https://www.estadao.com.br/blogs/blog/wp-content/uploads/sites/41/2022/02/parecercloroquina_090220224926.pdf
Nag K, Tripura K, Datta A, Karmakar N, Singh M, Singh M, et al. Effect of Hydroxychloroquine and Azithromycin Combination Use in COVID-19 Patients - An Umbrella Review. Indian J Community Med. 2024;49(1):22-7. https://doi.org/10.4103/ijcm.ijcm_983_22
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Derechos de autor 2024 Array